Erratum to: Invest New Drugs (2013) 31:742–750

DOI 10.1007/s10637-012-9881-z

In the original version of this article, three authors are missing. The complete list of authors and their current and former (at the time the work was performed) affiliations are provided. The additional authors declare no conflicts of interest.

In addition, pharmacodynamics assays performed to obtain absolute plasma concentrations of HGF, VEGF, soluble KDR and soluble Met as described in the original article were incorrectly attributed in the Methods section.

The following text…

“Absolute plasma concentrations of HGF, VEGF, soluble KDR and soluble Met were determined by two-site electrochemiluminescent immunoassay as described previously [1].”

…replaces the original text below:

“Plasma levels of soluble MET (sMET), HGF, soluble VEGFR2 (sVEGFR2), and VEGF-A were measured using enzyme-linked immunosorbent assay at Pathway Diagnostics, Malibu, California, USA (now Quest Diagnostics Biomarker Lab, Valencia, California, USA) and at Exelixis (for sMET).”

The following citation refers to the text added, above.

[1] Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res 2006;12:4154-62.

Finally, the following acknowledgement statement should be added:

“This work was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.”